These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 37627054)

  • 1. BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers.
    Castellani G; Buccarelli M; Arasi MB; Rossi S; Pisanu ME; Bellenghi M; Lintas C; Tabolacci C
    Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Therapy for Melanomas Without BRAF V600 Mutations.
    Menzer C; Hassel JC
    Curr Treat Options Oncol; 2022 Jun; 23(6):831-842. PubMed ID: 35380338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NFAT signalling is a novel target of oncogenic BRAF in metastatic melanoma.
    Flockhart RJ; Armstrong JL; Reynolds NJ; Lovat PE
    Br J Cancer; 2009 Oct; 101(8):1448-55. PubMed ID: 19724275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF somatic mutations in malignant melanoma and melanocytic naevi.
    Thomas NE
    Melanoma Res; 2006 Apr; 16(2):97-103. PubMed ID: 16567964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted Therapy in Advanced Melanoma With Rare
    Menzer C; Menzies AM; Carlino MS; Reijers I; Groen EJ; Eigentler T; de Groot JWB; van der Veldt AAM; Johnson DB; Meiss F; Schlaak M; Schilling B; Westgeest HM; Gutzmer R; Pföhler C; Meier F; Zimmer L; Suijkerbuijk KPM; Haalck T; Thoms KM; Herbschleb K; Leichsenring J; Menzer A; Kopp-Schneider A; Long GV; Kefford R; Enk A; Blank CU; Hassel JC
    J Clin Oncol; 2019 Nov; 37(33):3142-3151. PubMed ID: 31580757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro.
    Delyon J; Vallet A; Bernard-Cacciarella M; Kuzniak I; Reger de Moura C; Louveau B; Jouenne F; Mourah S; Lebbé C; Dumaz N
    Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.
    Dankner M; Rose AAN; Rajkumar S; Siegel PM; Watson IR
    Oncogene; 2018 Jun; 37(24):3183-3199. PubMed ID: 29540830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.
    Johnson GL; Stuhlmiller TJ; Angus SP; Zawistowski JS; Graves LM
    Clin Cancer Res; 2014 May; 20(10):2516-22. PubMed ID: 24664307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR.
    Reid AL; Freeman JB; Millward M; Ziman M; Gray ES
    Clin Biochem; 2015 Oct; 48(15):999-1002. PubMed ID: 25523300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pluripotency markers are differentially induced by MEK inhibition in thyroid and melanoma BRAFV600E cell lines.
    Dorris ER; Blackshields G; Sommerville G; Alhashemi M; Dias A; McEneaney V; Smyth P; O'Leary JJ; Sheils O
    Cancer Biol Ther; 2016 May; 17(5):526-42. PubMed ID: 26828826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activities of multiple cancer-related pathways are associated with BRAF mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells.
    Liu D; Liu X; Xing M
    Cell Cycle; 2014; 13(2):208-19. PubMed ID: 24200969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Encorafenib and binimetinib for the treatment of BRAF V600E/K-mutated melanoma.
    Rose AAN
    Drugs Today (Barc); 2019 Apr; 55(4):247-264. PubMed ID: 31050693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors.
    Faghfuri E; Nikfar S; Niaz K; Faramarzi MA; Abdollahi M
    Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):317-330. PubMed ID: 29363351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma proteome alterations by MAPK inhibitors in BRAF
    Babačić H; Eriksson H; Pernemalm M
    Neoplasia; 2021 Aug; 23(8):783-791. PubMed ID: 34246984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-V600E/K BRAF Mutations in Metastatic Melanoma: Molecular Description, Frequency, and Effectiveness of Targeted Therapy in a Large National Cohort.
    Girod M; Dalle S; Mortier L; Dalac S; Leccia MT; Dutriaux C; Montaudié H; de Quatrebarbes J; Lesimple T; Brunet-Possenti F; Saiag P; Maubec E; Legoupil D; Stoebner PE; Arnault JP; Lefevre W; Lebbe C; Dereure O
    JCO Precis Oncol; 2022 Nov; 6():e2200075. PubMed ID: 36356284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vemurafenib.
    Garbe C; Abusaif S; Eigentler TK
    Recent Results Cancer Res; 2014; 201():215-25. PubMed ID: 24756795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
    Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
    J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted Therapy for Melanoma.
    Wong DJ; Ribas A
    Cancer Treat Res; 2016; 167():251-62. PubMed ID: 26601866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma.
    Johnpulle RA; Johnson DB; Sosman JA
    Curr Oncol Rep; 2016 Jan; 18(1):6. PubMed ID: 26743513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.